Johnson & Johnson has been active this year, acquiring new assets and launching products for future growth.
Six key updates to know:
1. Johnson & Johnson DePuy Synthes announced plans to create 30 jobs at its Ireland hub after making a $41.16 million investment. The five-year research and development investment project aims to scale DePuy's activities at its Ireland Innovation Centre where it will establish a 3D printing program.
2. Johnson & Johnson’s subsidiary Ethicon closed its acquisition of robotic technologies company Auris Health on April 1. Ethicon paid $3.4 billion in cash and may pay an additional $2.35 billion if certain milestones are achieved.
3. DePuy acquired a surgical robot prototype from Orthotaxy and offered a first look at its features during the 2019 AAOS Annual Meeting, March 12-16 in Las Vegas.
4. Johnson & Johnson reported orthopedic sales dropped 2.1 percent in the first quarter of 2019, hitting $2.2 billion. While the U.S. sales were up 0.9 percent at $1.3 billion, international sales declined 6.2 percent to $885 million. The company's spine and other sales were down 5.5 percent internationally and flat in the U.S., hitting $465 million.
5. DePuy filed a lawsuit alleging its competitor, Orthofix, improperly converted Dothan-based Southeast Alabama Medical Center — which had been a "longtime" DePuy customer "worth millions of dollars" — into an Orthofix client. The lawsuit is still pending.
6. The Business Research Company that Wright Medical Group, Zimmer Biomet, Stryker and Exactech trail DePuy as the largest player in the minor orthopedic replacement implants market. The global minor orthopedic replacement implants market is expected to be worth more than $2 billion in 2021.